# TareBio

Source: https://onco.cc/companies/tarebio/  
OnCo record `tarebio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TareBio reads the immune cells already fighting a cancer in a patient's body and works backwards to design a vaccine that makes more of them, in weeks rather than years.

## Summary

TareBio's platform designs personalised or population-level vaccines by reading out the immune imprint, the T and B cells already engaged against a disease in the body, and reverse-engineering antigens that activate them, rather than predicting antigens from tumour sequencing alone. The company reports having run the platform end to end and produced a vaccine that cleared tumours in mice. It is a one-person Summer 2026 YC company; the work is preclinical.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: San Francisco, CA
- Type: biotech
- Website: https://tarebio.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/tarebio
- Official website: https://tarebio.com

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/tarebio.json